All In Biotech

Drug Trial Radar · NCT04422509

Lanadelumab for Treatment of COVID-19 Disease

Last checked: Nov 20, 2026Latest source record: Jul 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Oct 30, 2020

Primary completion

Feb 25, 2021

Study completion Apr 30, 2021

Sponsor

Lead sponsor
Radboud University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Takeda
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

So far little is very few drugs have demonstrated positive results for treatment of COVID19. Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in oxygen use. Yet the effect of the three dosages as according to the label dose was insufficient to maintain the clinical improvement in a small group of patients. The researchers argue that with the use of lanadelumab a more lasting effect can be reached due to its longer half life.

Conditions

  • COVID-19

Interventions

  • lanadelumabBiological

    single dose, or two doses administered iv

  • regular careOther

    no lanadelumab administration, treated according to regular care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. oxygenTime frame: 2 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Amsterdam UMC

    Amsterdam, Netherlands

  • Rijnstate hospital

    Arnhem, Netherlands

  • Radboudumc

    Nijmegen, Netherlands

  • UMC Utrecht

    Utrecht, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.